All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, August 10, 2022
Home » Blogs » BioWorld MedTech Perspectives » The real story: competing markets, not just emerging markets

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

The real story: competing markets, not just emerging markets

April 13, 2011
By Omar Ford
No Comments

Often times journalists go into interviews with pretty much a clear picture of what the story is going to be. There are few surprises – that is until that one kernel of information spills from the lips of a source and it completely steers the story in a different direction and gets you to look at a subject differently.

Well that happened to me during the Southeastern Medical Association Conference  held here in Atlanta recently.  One of the panelists was speaking during a session called successful pathways to medical device innovation, when all of a sudden he paused - and started talking about China and its potential impact on the med-tech landscape here in the U.S.

Instead of the same old song and dance of China becoming an emerging market and ripe opportunity for U.S. companies to take part in, the speaker made it sound like the nation was a competing market that was going to eventually take share away from U.S. device makers.

And these weren’t the musings of one lone med-device executive.

Recently I spoke with consulting firm Sagentia’s CEO Brent Hudson, who echoed similar statements – albeit nearly at the end of our conversation.

He noted that the Western med-tech firms are aware of China becoming a dominant player in the space and said that med-tech companies are trying various approaches to get a handle on the expansion into the Western market.

“I don’t speak to a single company that isn’t worried about it. Some are trying a partnership approach with say, Chinese device manufacturers,” Hudson told me.  He added that others were trying a more dominant approach.

 I think the take away from all this, is that the deeper story isn’t so much that these plush new emerging markets are waiting for U.S. markets to come to them.  I think the real key point is, these overseas ‘emerging markets’ are competitors and could have the potential to take away significant market share from U.S. firms.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Aug. 9, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Aug. 9, 2022.
  • Amvuttra

    Alnylam’s Amvuttra rare disease drug among positive recommendations from Europe’s CHMP

    BioWorld
    Alnylam Pharmaceuticals Inc.’s Amvuttra (vutrisiran), a treatment for the rare disease hereditary transthyretin-mediated amyloidosis, was among medicines...
  • Pig organ cells

    Whole body cellular function recovery in pigs after death

    Science
    A new system for restoring cell function and tissues in mammals after death could expand the availability of organs for transplantation. The research also opens...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing